Journal of Endocrinological Investigation

, Volume 18, Issue 6, pp 436–440 | Cite as

Prolactinoma in 53 men: Clinical characteristics and modes of treatment (male prolactinoma)

  • Meir Berezin
  • I. Shimon
  • M. Hadani


The data of 53 men treated for hyperprolactinemia were reviewed retrospectively to determine the efficacy of the medical and surgical treatment. The clinical assessment, radiological and neuro-ophthalmological investigations and hormonal measurements were performed before treatment as well as during the follow-up period. Imaging evaluation included computed tomography and/or nuclear magnetic resonance of the pituitary. The hormonal profile examined was PRL, FSH, LH and testosterone, as well as TSH, T4, T3 and Cortisol. Thirty patients were treated solely by dopamine agonists (DA), twenty-two men had pituitary surgery in addition to DA treatment, and one patient was operated with no need for medical treatment. Decreased sexual function was the most frequent presenting symptom (85% of the men). Most of the patients had large invasive macroadenomas, with suprasellar extension. More than 40% had visual field defects. Baseline PRL (mean ± SE) was 51,842 ± 9,292 mU/L and decreased to a level below 575 mU/L in 70% of the patients after DA therapy. Mean testosterone, FSH, and LH levels increased slightly but significantly from the low baseline values. Complete clinical response to DA was achieved in 49% of the men and the tumor mass disappeared entirely in 21%, and incompletely in 42%. The surgical success rate (transsphenoidal or trans-cranial operation) was low — only one of the 23 patients operated recovered completely, and most of the patients were left with hormonal deficits and hyperprolactinemia. These findings indicate that continuous medical treatment with DA should be the preferred mode of treatment for male prolactinomas. Removal of these large tumors is recommended only when the tumors are life-threatening or if drug resistance or severe adverse reactions to DA develop.


Prolactin pituitary adenoma men dopamine antagonists 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hulting A.L., Muhr C., Lundberg P.O., Werner S. Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Med. Scand. 217: 101, 1985.PubMedCrossRefGoogle Scholar
  2. 2.
    Eversmann T., Eichinger R., Fahlbusch R., Rjosk H.K., von Werder K. Die Hyperprolaktinemie beim Mann: Klinik and Therapie. Schweiz. Med. Wochenschr. 11: 1782, 1981.Google Scholar
  3. 3.
    Friesen H.G., Tolis G. The use of bromocriptine in the galactorrhea-amen-orrhoea syndromes: the Canadian co-operative study. Clin. Endocrinol (Oxf.) 6(Suppl.): 915, 1977Google Scholar
  4. 4.
    Gomez F., Reyes F.I., Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia: Clinical findings, endocrine features and therapeutic responses in 56 cases. Am. J. Med. 62: 648, 1977.PubMedCrossRefGoogle Scholar
  5. 5.
    Kleinberg D.L., Noel G.L, Frantz A.G. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N. Engl. J. Med. 296: 589, 1977.PubMedCrossRefGoogle Scholar
  6. 6.
    Jacobs H.S. Prolactin and amenorrhea. N. Engl. J. Med. 295: 954, 1976.PubMedCrossRefGoogle Scholar
  7. 7.
    Carter J.N., Tyson J.E., Tolis G., van Vliet S., Faiman C., Friesen H.G. Prolactin-secreting tumors and hypogonadism in 22 men. N.Engl. J. Med. 299: 847, 1978.PubMedCrossRefGoogle Scholar
  8. 8.
    Spark R.F., Wills C.A., O’Reilly G., Ransil B.J., Bergland R. Hyperprolactinemia in males with and without pituitary macroadenomas. Lancet 2: 129, 1982.PubMedCrossRefGoogle Scholar
  9. 9.
    Prescott R.W.G., Johnston D.G., Kendall-Taylor P. et al. Hyperprolactinemia in men-response to bromocriptine therapy. Lancet 1: 245, 1982.PubMedCrossRefGoogle Scholar
  10. 10.
    Melmed S., Braunstein G.D. Chang R.J., Becker D.P. Pituitary tumors secreting growth hormone and prolactin. Ann. Intern. Med. 105: 238, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Llyod R.V., Jin L., Fields K., Kulig E. Effects of estrogens on pituitary cell and prolactinoma tumor growth. Pathol. Res. Pract. 187: 632, 1991.CrossRefGoogle Scholar
  12. 12.
    Barrow D.L., Mizuno J., Tidall G.T. Management of prolactinomas associated with very high serum prolactin levels. J. Neurosurg. 68: 554, 1988.PubMedCrossRefGoogle Scholar
  13. 13.
    Molitch M.E. Pathologic hyperprolactinemia in Endocrinology and Metabolism. Clin. North Am. 21: 877, 1992.Google Scholar
  14. 14.
    Grossman A., Cohen B.L., Charlesworth M., Plowman P.N., Rees Lesley H., Wass J.A.H., Jones A.E., Besser G.M. Treatment of prolactinomas with megavoltage radiotherapy. Br.Med. J. 288: 1105, 1984.CrossRefGoogle Scholar
  15. 15.
    Nagulsparen M., Ang V., Jenkins J.S. Bromocriptine treatment of males with pituitary tumors, hyperprolactinemia, and hypogonadism. Clin. Endocrinol. 9: 73, 1978.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1995

Authors and Affiliations

  • Meir Berezin
    • 1
  • I. Shimon
    • 1
  • M. Hadani
    • 2
  1. 1.Institute of EndocrinologySheba Medical CenterTel HashomerIsrael
  2. 2.Departement of NeurosurgerySheba Medical CenterTel HashomerIsrael

Personalised recommendations